Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits. The lead product candidate, ninerafaxstat, is currently in Phase 2 clinical development in three indications: nHCM, stable angina, and HFpEF. For additional information, please visit www.imbria.com.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $40.7M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | SV Health ... | svhealthin... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 03.07.2020 | - | $40.7M | - | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 07.11.2023 | Imbria Reports Positive Topline Results for Investigational ... | – The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-wee... | svhealthin... |
| 05.06.2023 | Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPRO... | – Enrollment exceeded expectations, thus highlighting the large unmet need in non-obstructive hypert... | svhealthin... |
| 26.08.2022 | Imbria Presents Positive Clinical Data for Ninerafaxstat fro... | BOSTON, Mass., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, car... | svhealthin... |
| 22.08.2022 | Imbria Pharmaceuticals to Present Phase 2a Data from the Nin... | BOSTON, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, car... | svhealthin... |
| 24.03.2022 | Imbria Pharmaceuticals Appoints John Young to its Board of D... | BOSTON, Mass., March 24, 2022 – Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic com... | svhealthin... |